Welcome to our dedicated page for Galmed Pharmaceu SEC filings (Ticker: GLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galmed Pharmaceuticals Ltd. (GLMD) SEC filings page on Stock Titan compiles the company’s U.S. regulatory disclosures, with AI-assisted summaries to help interpret the information. As a foreign private issuer listed on The Nasdaq Capital Market, Galmed furnishes reports on Form 6-K and files an annual report on Form 20-F, detailing its clinical programs, financial position and key risks.
For a clinical-stage biopharmaceutical company focused on Aramchol, filings provide context on research and development spending, net losses, cash, short-term deposits and marketable securities, all of which are central to assessing funding for liver, GI oncology and cardiometabolic studies. Interim condensed consolidated financial statements, included in 6-K submissions for periods such as the three and six months or three and nine months ended on specific dates, outline operating expenses, financial income, impairment charges and changes in stockholders’ equity.
Galmed’s 6-K filings also frequently attach press releases as exhibits, covering topics like AM-001 bioavailability results for Aramchol meglumine, top-line findings from oncology mechanism-of-action studies, new use patents for Aramchol combinations, quarterly financial results and adoption of a digital asset management strategy. Other 6-Ks document corporate actions, including notices and outcomes of shareholder meetings and amendments to the Articles of Association to increase authorized share capital.
On this page, users can quickly access Galmed’s 20-F annual report for a comprehensive discussion of risk factors, business overview, and detailed financial statements, and review successive 6-Ks for updates between annual filings. Stock Titan’s AI tools highlight key points from lengthy documents, helping readers understand how Galmed describes the development of Aramchol for liver disease, GI cancers and cardiometabolic indications, as well as how it discloses treasury policies such as its crypto-related strategy.
Galmed Pharmaceuticals reported that its Annual General Meeting of Shareholders was convened but adjourned for one day due to lack of quorum. The meeting will reconvene on October 29, 2025 at 4:00 p.m. Israel time at Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.
This report is incorporated by reference into the company’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and Form F-3 (Nos. 333-272722, 333-283241).
Galmed Pharmaceuticals Ltd. filed a Form S-8 to register an additional 500,000 ordinary shares, par value NIS 1.80 per share, for issuance under its 2013 Incentive Share Option Plan. This filing builds on prior S-8 registrations from 2015, 2018, and 2025 for the same plan, allowing the company to continue granting equity-based awards to eligible participants. The company incorporates by reference its latest Form 20-F, multiple Form 6-K reports, and the description of its ordinary shares, and includes legal and audit consents and a filing fee calculation as exhibits. The registration statement is signed by senior management, directors, and the company’s authorized U.S. representative.
Galmed Pharmaceuticals Ltd. reports it will hold its Annual General Meeting of Shareholders on October 28, 2025, at 4:00 p.m. (Israel time) at the offices of Meitar | Law Offices in Ramat Gan, Israel. The company has provided a Notice of the Annual General Meeting and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2. This report on Form 6-K is also incorporated by reference into Galmed’s existing Registration Statements on Form S-8 and Form F-3.
Galmed Pharmaceuticals Ltd. reported interim financial details as of June 30, 2025. The company held $7.5 million in short-term deposits, $0.1 million in restricted cash and $8.1 million in marketable debt securities. Investment in an associate is shown at $1.593 million (down from $2.119 million). Trade payables were $1.369 million. Ordinary shares outstanding increased to 5,303,050 from 1,664,884, reflecting multiple issuances during the period. The company reported an accumulated deficit of $204.1 million and operating expenses for the period (total operating expenses shown at $2,109 thousand). The filing discloses multiple equity financings including a SEPA commitment, ATM sales totaling approximately $7.7 million gross, and proceeds of approximately $5.1 million from issuances to YA.
Galmed Pharmaceuticals reports several corporate updates. The company issued a press release announcing a new digital asset management strategy aimed at enhancing capital efficiency and driving shareholder value. Galmed also terminated a previously announced binding term sheet with Entomus s.r.o. for an exclusive license to develop and commercialize a Self-Emulsifying Drug Delivery System (SEDDS) formulation. Instead, a new UK-based company has been formed to pursue the SEDDS project, and it is contemplated that Galmed will acquire up to 25% of this entity’s share capital, subject to definitive agreements and board approval. The company additionally filed supplemental risk factor disclosures that update prior risk discussions and incorporated these materials into its existing Form S-8 and Form F-3 registration statements.
Galmed Pharmaceuticals Ltd. reports that its shareholders approved an amended and restated set of articles of association at a Special General Meeting held on August 15, 2025. The proposal was described in a previously distributed proxy statement and was approved with the requisite majority under Israeli Companies Law. The updated articles of association are provided as an exhibit and this report is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.
CVI Investments, Inc. and Heights Capital Management, Inc. disclosed a beneficial position in Galmed Pharmaceuticals Ltd. consisting of 173,333 ordinary shares, equal to 7.1% of the class based on 2,258,034 shares outstanding as reported by the company as of March 31, 2025. The reported position represents shares issuable upon exercise of warrants, and the warrants include an exercise limitation that prevents exercises that would push ownership above 9.99%. Heights Capital serves as investment manager to CVI and may have shared voting and dispositive power over the reported shares; both reporting persons disclaim beneficial ownership except for their pecuniary interest.